Corrigendum to “A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis” [International Journal of Gynecology and Obstetrics 108 (2010) 21–25]

Günter Köhler, Thomas Faustmann, Christoph Gerlinger, Christian Seitz, Alfred O. Mueck
In: International Journal of Gynecology & Obstetrics · 2011 · vol. 112(3) , pp. 257 · doi:10.1016/j.ijgo.2010.12.001 · W2168368105
erratum OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This corrigendum clarifies that analyses were based on the full-analysis set, adjusting Fig. 2 for missing rAFS scores and detailing histologic findings for endometriosis in the 2-mg and 4-mg dienogest groups.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The authors wish to clarify that analyses in the paper are based on the full-analysis set (FAS), excluding patients for whom data were unavailable. For the revised American Fertility Society (rAFS) score, data were unavailable in 9.5% of patients in the 2-mg group group at 24 weeks. The columns in Fig. 2 are adjusted to 100%, after excluding these missing data. Histologic examination at 24 weeks in the 2-mg and 4-mg groups identified endometriosis in 33.3% and 46.7%, and no endometriosis in 28.6% and 30.0% of women, with data unavailable in 38.1% and 23.3%, respectively.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK